StreetInsider.com News Articles

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026

Wed, 14 Oct 2026 16:01:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

To participate in the conference call by telephone, dial 1-800-343-4849 or 1-203-518-9848 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors"

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026

Wed, 14 Oct 2026 16:01:00 -0400

Form 4 MARAVAI LIFESCIENCES For: Oct 08 Filed by: Brust Bernd

Fri, 09 Oct 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20261009/27172440.html

TD Cowen Starts Maravai LifeScience Holdings Inc. (MRVI) at Buy

Mon, 05 Oct 2026 06:09:50 -0400

(Updated - October 5, 2026 6:09 AM EDT)

TD Cowen analyst Brendan Smith initiates coverage on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) with a Buy rating, PT $9.00.

The analyst comments "Core CleanCap rev growth is returning, but the larger, more undervalued opportunity is converting a broad non-COVID mRNA pipeline from discovery into higher-value GMP. With a leaner cost base than consensus appreciates & significant capacity on hand, rev growth should drive outsized earnings power. 6.5x EV/'27 sales multiple (still a discount to ~8x comp group avg) supports our $9 PT & Buy rating."

For an analyst ratings summary and ratings history on

TD Cowen Starts Maravai LifeScience Holdings Inc. (MRVI) at Buy

Mon, 05 Oct 2026 06:09:50 -0400

(Updated - October 5, 2026 6:09 AM EDT)

TD Cowen analyst Brendan Smith initiates coverage on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) with a Buy rating, PT $9.00.

For an analyst ratings summary and ratings history on

Form 4 MARAVAI LIFESCIENCES For: Sep 30 Filed by: Asarpota Rajesh

Thu, 01 Oct 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20261001/27137489.html

Form SCHEDULE 13G MARAVAI LIFESCIENCES Filed by: MILLENNIUM MANAGEMENT LLC

Tue, 29 Sep 2026 18:33:00 -0400

si-local-file:///var/storage/secattach/20260929/27123699.html

TriLink wins second China patent for CleanCap mRNA technology

Tue, 29 Sep 2026 16:01:36 -0400

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ: MRVI), has been granted a second patent in China for its CleanCap technology, according to a company statement.

The China National Intellectual Property Administration issued patent number ZL202511246658.5, titled "Compositions and Methods for Synthesizing 5'-Capped RNAs." The new patent covers the CleanCap cap analog compounds themselves, RNA molecules containing those compounds, cells with such RNA molecules, and pharmaceutical compositions that incorporate CleanCap-capped RNA.

The newly granted patent is separate from a previously announced Chinese patent, ZL202511246578.X, which covers methods of synthesizing capped RNA molecules. Together, the two patents cover both the process of making

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

Tue, 29 Sep 2026 16:01:00 -0400

New Patent Protects the CleanCap® Cap Analog Compounds Themselves and mRNA-Based Pharmaceutical Compositions — Extending Beyond Method Claims to Cover the Molecules at the Heart of Modern mRNA Medicines

SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands the

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

Tue, 29 Sep 2026 16:01:00 -0400

UBS Reiterates Neutral Rating on Maravai LifeScience Holdings Inc. (MRVI)

Wed, 09 Sep 2026 06:07:59 -0400

UBS analyst Douglas Schenkel reiterated a Neutral rating and $8.00 price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI)

For an analyst ratings summary and ratings history on Maravai LifeScience Holdings Inc. click here. For more ratings news on Maravai LifeScience Holdings Inc. click here.

Shares of Maravai LifeScience Holdings Inc. closed at $7.19 yesterday.

Maravai LifeSciences (MRVI) call put ratio 22 calls to 1 put with a focus on December 5, 7.5 and 10 calls as share price up 25%

Wed, 19 Aug 2026 11:27:05 -0400

Maravai LifeSciences (NASDAQ: MRVI) 30-day call option implied volatility is 131; compared to its 52-week range of 65 to 187. Call put ratio 22 calls to 1 put with a focus on December 5, 7.5 and 10 calls as share price up 25%.

Maravai LifeSciences (MRVI) call put ratio 1 call to 4 puts into share price up before the bell

Wed, 19 Aug 2026 09:15:05 -0400

Maravai LifeSciences (NASDAQ: MRVI) 30-day call option implied volatility is 187; compared to its 52-week range of 65 to 187. Call put ratio 1 call to 4 puts.

Form SCHEDULE 13G/A MARAVAI LIFESCIENCES Filed by: FELDMAN STUART

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921901.html

Form SCHEDULE 13G/A MARAVAI LIFESCIENCES Filed by: FELDMAN STUART

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921901.html

Form 4 MARAVAI LIFESCIENCES For: Aug 10 Filed by: Brust Bernd

Tue, 11 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260811/26906646.html

Form 4 MARAVAI LIFESCIENCES For: Aug 10 Filed by: Brust Bernd

Tue, 11 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260811/26906646.html

Form 10-Q MARAVAI LIFESCIENCES For: Jun 30

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890911.html

Form 10-Q MARAVAI LIFESCIENCES For: Jun 30

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890911.html

Maravai LifeScience Holdings Inc. (MRVI) PT Raised to $6.50 at Wells Fargo

Fri, 07 Aug 2026 08:24:06 -0400

Wells Fargo analyst Evan Stampler raised the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $6.50 (from $5.50) while maintaining a Overweight rating.

Maravai LifeSciences (MRVI) Tops Q2 EPS by 2c

Thu, 06 Aug 2026 16:26:54 -0400

Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $51.4 million versus the consensus estimate of $48.68 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

Form 8-K MARAVAI LIFESCIENCES For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883685.html

Form 8-K MARAVAI LIFESCIENCES For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883685.html

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates.

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the